Skip to main content

Site notifications

AusPAR: SARS-CoV-2 rS with Matrix-M adjuvant

Australian Public Assessment Report
Device/Product Name
Nuvaxovid
Active ingredients
SARS-CoV-2 rS with Matrix-M adjuvant
AusPAR Date
Published
Submission Number
PM-2021-00623-1-2
Submission Type
New biological entity
Decision
Approved for provisional registration

Help us improve the Therapeutic Goods Administration site